Ignite Creation Date:
2025-12-25 @ 4:19 AM
Ignite Modification Date:
2026-03-03 @ 2:28 AM
Study NCT ID:
NCT02973620
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2018-05-16
First Post:
2016-11-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Levosimendan Compassionate Use in Pediatric Patients With Advanced Decompensated Heart Failure
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'removedCountries': ['United States']}, 'conditionBrowseModule': {'meshes': [{'id': 'D006333', 'term': 'Heart Failure'}], 'ancestors': [{'id': 'D006331', 'term': 'Heart Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077464', 'term': 'Simendan'}], 'ancestors': [{'id': 'D006835', 'term': 'Hydrazones'}, {'id': 'D006834', 'term': 'Hydrazines'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D011724', 'term': 'Pyridazines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}]}}, 'protocolSection': {'designModule': {'studyType': 'EXPANDED_ACCESS'}, 'statusModule': {'overallStatus': 'NO_LONGER_AVAILABLE', 'statusVerifiedDate': '2018-05', 'lastUpdateSubmitDate': '2018-05-10', 'studyFirstSubmitDate': '2016-11-22', 'studyFirstSubmitQcDate': '2016-11-22', 'lastUpdatePostDateStruct': {'date': '2018-05-16', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2016-11-25', 'type': 'ESTIMATED'}}, 'conditionsModule': {'conditions': ['Heart Decompensation']}, 'descriptionModule': {'briefSummary': 'Open label study of levosimendan; planned comparison for effectiveness and safety to historic matched case controls from participating sites.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT'], 'maximumAge': '18 Years', 'eligibilityCriteria': "General Eligibility\n\nAll patients must meet at least one of the following definitions of failed standard therapy of decompensated heart failure:\n\nDefinition for failure of standard therapy:\n\n1. Decompensated heart failure refractory to standard therapy (Milrinone of ≥0.5mcg/kg/min for \\>48 hours with EF \\<35%) including any of the following:\n\n * (SaO2 - SmVO2) \\> 30 % or lactate \\>3 AND/OR\n * Need for second inotropic agent AND/OR\n * Need for positive pressure ventilation AND\n * Patient not qualifying for long term ventricular assist device support or transplant at the time of assessment.\n2. Cardiogenic shock with acute decompensated heart failure (requiring positive pressure ventilation and addition of inotropic support with or without use of Milrinone with EF \\<35%) refractory to therapy for more than 48h including any or all of the following:\n\n * (SaO2 - SmVO2) \\> 30 % or lactate \\>3\n * Patient not qualifying for long term ventricular assist device support or transplant at the time of assessment.\n * Potential need for short-term mechanical circulatory support.\n3. Failure to wean off ECMO support with use of standard inotropic / vasoconstrictor support.\n\nInclusion Criteria:\n\n1. Male or female, ≤18 years of age with acute or acute on chronic decompensated heart failure.\n2. Male or female, ≤18 years of age on ECMO support and unable to wean from ECMO support.\n3. Informed Consent signed by the subject's parents or their legally acceptable representatives indicating that they understand the purpose of and procedures required for expanded access and are willing to participate in the study.\n4. Patients meeting one of the following definitions of failed standard therapy of decompensated heart failure\n\nExclusion Criteria:\n\n1. Patients \\< 36 weeks gestational age\n2. Patients weighing \\< 2 kg\n3. Obstructive cardiomyopathy, constrictive pericarditis, pericardial tamponade\n4. Estimated glomerular filtration rate (eGRF) \\< 30 mL/min/1.73m2.\n5. Known allergic reaction or sensitivity to levosimendan or excipients.\n6. A history of Torsades de Pointes, uncorrectable hypo- or hyperkalemia, uncorrectable hypo- or hypercalcemia\n7. Pregnant, suspected to be pregnant, or breast-feeding.\n8. Inability or unwillingness of subject or legal guardian/representative to give written informed consent."}, 'identificationModule': {'nctId': 'NCT02973620', 'briefTitle': 'Levosimendan Compassionate Use in Pediatric Patients With Advanced Decompensated Heart Failure', 'organization': {'class': 'INDUSTRY', 'fullName': 'Tenax Therapeutics, Inc.'}, 'officialTitle': 'Expanded Access Protocol; Intermediate Size Protocol: Levosimendan Compassionate Use in Pediatric Patients With Advanced Decompensated Heart Failure Who Are Refractory to Standard Therapy', 'orgStudyIdInfo': {'id': 'TNX-LVO-02'}}, 'armsInterventionsModule': {'interventions': [{'name': 'Levosimendan', 'type': 'DRUG', 'otherNames': ['Simdax'], 'description': 'levosimendan infusion started at 0.1 mcg/kg/min for 6-12 hours, increased to 0.2 mcg/kg/min for 24-36 hours'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Tenax Therapeutics, Inc.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}